Cargando…

Methylation of PD-1 Promoter Gene as New Prognostic Marker for IDH Mutant Low-Grade Glioma?

Detalles Bibliográficos
Autor principal:	Marosi, Christine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5925618/ https://www.ncbi.nlm.nih.gov/pubmed/29487022 http://dx.doi.org/10.1016/j.ebiom.2018.02.018

Ejemplares similares

Duchenne muscular dystrophy gene expression is an independent prognostic marker for IDH mutant low-grade glioma
por: Naidoo, Michael, et al.
Publicado: (2022)

Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers
por: Unruh, Dusten, et al.
Publicado: (2019)

Hypermethylation of LATS2 Promoter and Its Prognostic Value in IDH-Mutated Low-Grade Gliomas
por: Gu, Yuan, et al.
Publicado: (2020)

MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma
por: Molloy, Abigail R, et al.
Publicado: (2020)

The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033
por: Bady, Pierre, et al.
Publicado: (2018)

PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations
por: Röver, Lea Kristin, et al.
Publicado: (2018)

Therapies for IDH-Mutant Gliomas
por: Alshiekh Nasany, Ruham, et al.
Publicado: (2023)

Mutant IDH1 Promotes Glioma Formation In Vivo
por: Philip, Beatrice, et al.
Publicado: (2018)

Pharmacoresistant seizures and IDH mutation in low-grade gliomas
por: Correia, Carlos Eduardo, et al.
Publicado: (2021)

Longitudinal DNA methylation analysis of adult-type IDH-mutant gliomas
por: Ferreyra Vega, Sandra, et al.
Publicado: (2023)

An Immune-Related Prognostic Signature for Predicting Clinical Outcomes and Immune Landscape in IDH-Mutant Lower-Grade Gliomas
por: Xiao, Gang, et al.
Publicado: (2021)

Clinicopathological associations and prognostic values of IDH1 gene mutation, MGMT gene promoter methylation, and PD-L1 expressions in high-grade glioma treated with standard treatment
por: July, Julius, et al.
Publicado: (2020)

Promoter Methylation Analysis of IDH Genes in Human Gliomas
por: Flanagan, Simon, et al.
Publicado: (2012)

Is intracranial volume a risk factor for IDH-mutant low-grade glioma? A case–control study
por: Sagberg, Lisa Millgård, et al.
Publicado: (2022)

Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
por: Mellinghoff, Ingo K., et al.
Publicado: (2023)

Postoperative risk of IDH-mutant glioma–associated seizures and their potential management with IDH-mutant inhibitors
por: Drumm, Michael R., et al.
Publicado: (2023)

Retrospective examination of pseudoprogression in IDH mutant gliomas
por: Wetzel, Ethan A, et al.
Publicado: (2023)

Stalled oligodendrocyte differentiation in IDH-mutant gliomas
por: Wei, Yanfei, et al.
Publicado: (2023)

Updates on the WHO diagnosis of IDH-mutant glioma
por: Reuss, David.E.
Publicado: (2023)

Identification of a Prognostic Hypoxia-Associated Gene Set in IDH-Mutant Glioma
por: Dao Trong, Philip, et al.
Publicado: (2018)

MPC-01 PROGNOSTIC ROLE OF TERT PROMOTER IMPROVES THE STRATIFICATION OF IDH-MUTATED LOWER GRADE GLIOMA
por: Arita, Hideyuki, et al.
Publicado: (2019)

Early Surgery Prolongs Professional Activity in IDH Mutant Low-Grade Glioma Patients: A Policy Change Analysis
por: Robe, Pierre A., et al.
Publicado: (2022)

Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma
por: Wijnenga, Maarten M. J., et al.
Publicado: (2018)

Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis
por: Lee, Kwanghoon, et al.
Publicado: (2023)

Pseudoprogression in low-grade glioma
por: Slater, Jason M., et al.
Publicado: (2019)

LGG-03. INCIDENCE AND OUTCOME OF PEDIATRIC IDH-MUTANT GLIOMA
por: Yeo, Kee Kiat, et al.
Publicado: (2020)

The neural stem-cell marker CD24 is specifically upregulated in IDH-mutant glioma
por: Tiburcio, Patricia D.B., et al.
Publicado: (2020)

Identification of IDH-mutant gliomas by a prognostic signature according to gene expression profiling
por: Wang, Qiangwei, et al.
Publicado: (2018)

DDRE-12. HETEROGENOUS RESPONSE OF IDH-MUTANT AND IDH-WT GLIOMA TO NAMPT INHIBITION
por: Rahman, Masum, et al.
Publicado: (2021)

Insulator dysfunction and oncogene activation in IDH mutant gliomas
por: Flavahan, William A., et al.
Publicado: (2015)

Metabolic Reprogramming in Mutant IDH1 Glioma Cells
por: Izquierdo-Garcia, Jose L., et al.
Publicado: (2015)

Epigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas
por: Park, Jong-Whi, et al.
Publicado: (2019)

Malignant Progression of an IDH Mutant Brainstem Glioma in Adult
por: SANO, Kenshi, et al.
Publicado: (2021)

Proteome-based insights for IDH-mutant glioma classification
por: Leu, Severina, et al.
Publicado: (2023)

Mutant IDH in Gliomas: Role in Cancer and Treatment Options
por: Solomou, Georgios, et al.
Publicado: (2023)

Systematically profiling the expression of eIF3 subunits in glioma reveals the expression of eIF3i has prognostic value in IDH-mutant lower grade glioma
por: Chai, Rui-Chao, et al.
Publicado: (2019)

MPC-2 Clinical course and prognosis of lower-grade glioma, IDH wildtype and pTERT mutant
por: Takahashi, Yoshinobu, et al.
Publicado: (2021)

Computational Analysis of IDH1, IDH2, and TP53 Mutations in Low-Grade Gliomas Including Oligodendrogliomas and Astrocytomas
por: Bendahou, Mohammed Amine, et al.
Publicado: (2020)

Seizures in patients with IDH-mutated lower grade gliomas
por: Carstam, Louise, et al.
Publicado: (2022)

Increased Radiation-Associated T-Cell Infiltration in Recurrent IDH-Mutant Glioma
por: Makarevic, Anastasia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8f4cput5ej8i8lh1ug3st63ip4